| abstract |
Delayed drug formulation, CHARACTERIZED because they contain a combination of an opioid chosen from the group comprising morphine, hydromorphone, codeine, oxycodone, dihydrocodeine, dextropropoxyphene, buprenorphine, levometadone, fentanyl, sufentanil, etorphine, pentazocine, tilidorphine, tramadol, dihydrochlorine , pethidine, piritramide or a physiologically tolerable salt thereof; an a-agonist chosen from the group comprising clonidine, guanfacine, guanabenz, lofexidine, adrenaline, methyldopa, norepinephrine, methoxamine, oxymetazoline, xylometazoline, terizoline, ST-91, medetomidine, dexmedetomidine, agmatine, UK14,304-para-amino , U-47, 476A, DJ-741, ICI-106270, xylazine, talipexole (BHT-920), nafazoline, tizanidine or a physiologically tolerable salt thereof; and lactose or calcium monoacid phosphate, with or without other pharmaceutical excipients. |